Effect of inflammation on voriconazole levels in patients with invasive pulmonary aspergillosis
DOI:
https://doi.org/10.3855/jidc.19290Keywords:
voriconazole, COVID-19-associated aspergillosis, invasive pulmonary aspergillosis, inflammation, therapeutic drug monitoringAbstract
Introduction: Voriconazole (VCZ) serum concentrations may be affected by many factors, such as drug-drug interactions, liver dysfunction, genetic polymorphism, and inflammation. This study aimed to determine the relationship between VCZ measured trough plasma levels and C-reactive protein levels in patients with coronavirus disease 2019 (COVID-19)-associated aspergillosis (CAPA) and invasive pulmonary aspergillosis (IPA).
Methodology: Patients who were > 18 years of age, received VCZ treatment for IPA or CAPA in our hospital between March 2020 and April 2021, and had their VCZ level monitored, were included in this retrospective study.
Results: A total of 85 patients (35 diagnosed with CAPA) were included in this study. Forty-three patients (50.6%) had VCZ levels in the therapeutic range, 4 (4.7%) were sub-therapeutic, and 38 (44.7%) were supra-therapeutic. Inflammatory markers were significantly higher in patients with supra-therapeutic levels (p < 0.05). Supra-therapeutic levels and VCZ-related adverse effects were significantly more frequent in CAPA patients than in IPA patients (p = 0.011 and p = 0.002, respectively).
Conclusions: Patients diagnosed with CAPA were more prone to adverse effects and supra-therapeutic VCZ levels. More frequent therapeutic drug monitoring is recommended in this patient population.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pinar Bakir Ekinci, Emre Kara, Ahmet Gorkem Er, Asli Pinar, Ahmet Cagkan Inkaya, Kutay Demirkan, Gokhan Metan, Omrum Uzun
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
